Limits...
Recombinant human thrombopoietin treatment promotes hematopoiesis recovery in patients with severe aplastic anemia receiving immunosuppressive therapy.

Wang H, Dong Q, Fu R, Qu W, Ruan E, Wang G, Liu H, Wu Y, Song J, Xing L, Guan J, Li L, Shao Z - Biomed Res Int (2015)

Bottom Line: Hematologic response, bone marrow megakaryocyte recovery, and time to transfusion independence were compared.Subjects receiving rhTPO presented an elevated number of megakaryocytes at 3, 6, and 9 months when compared with those without treatment (P = 0.025, P = 0.021, and P = 0.011, resp.).Overall survival rate presented no differences between the two groups. rhTPO could improve hematologic response and promote bone marrow recovery in SAA patients receiving IST.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin 300052, China.

ABSTRACT

Objective: To assess the effectiveness of recombinant human thrombopoietin (rhTPO) in severe aplastic anemia (SAA) patients receiving immunosuppressive therapy (IST).

Methods: Eighty-eight SAA patients receiving IST from January 2007 to December 2012 were included in this retrospective analysis. Of these, 40 subjects received rhTPO treatment (15000 U, subcutaneously, three times a week). rhTPO treatment was discontinued when the platelet count returned to normal range. Hematologic response, bone marrow megakaryocyte recovery, and time to transfusion independence were compared.

Results: Hematologic response was achieved in 42.5%, 62.5%, and 67.5% of patients receiving rhTPO and 22.9%, 41.6%, and 47.9% of patients not receiving rhTPO at 3, 6, and 9 months after treatment, respectively (P = 0.0665, P = 0.0579, and P = 0.0847, resp.). Subjects receiving rhTPO presented an elevated number of megakaryocytes at 3, 6, and 9 months when compared with those without treatment (P = 0.025, P = 0.021, and P = 0.011, resp.). The time to platelet and red blood cell transfusion independence was shorter in patients who received rhTPO than in those without rhTPO treatment. Overall survival rate presented no differences between the two groups.

Conclusion: rhTPO could improve hematologic response and promote bone marrow recovery in SAA patients receiving IST.

Show MeSH

Related in: MedlinePlus

Bone marrow megakaryocytes in patients treated with and without rhTPO at 3, 6, and 9 months (all P < 0.05).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4377357&req=5

fig1: Bone marrow megakaryocytes in patients treated with and without rhTPO at 3, 6, and 9 months (all P < 0.05).

Mentions: In patients treated with rhTPO, megakaryocyte counts (according to bone marrow biopsies of 1 cm × 1 cm) were 9 (n = 32, range 0–35) at 3 months, 13 (n = 31, range 0–41) at 6 months, and 32 (n = 29, range 0–79) at 9 months. The number of megakaryocytes in patients without rhTPO treatment was 3 (n = 37, range 0–5), 5 (n = 34, range 0–19), and 9 (n = 32, range 0–42) at 3, 6, and 9 months, respectively. In our study, there was a significant increase of megakaryocytes in patients treated with rhTPO at 3, 6, and 9 months (P = 0.025, P = 0.021, and P = 0.011, resp.) (Table 3, Figure 1).


Recombinant human thrombopoietin treatment promotes hematopoiesis recovery in patients with severe aplastic anemia receiving immunosuppressive therapy.

Wang H, Dong Q, Fu R, Qu W, Ruan E, Wang G, Liu H, Wu Y, Song J, Xing L, Guan J, Li L, Shao Z - Biomed Res Int (2015)

Bone marrow megakaryocytes in patients treated with and without rhTPO at 3, 6, and 9 months (all P < 0.05).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4377357&req=5

fig1: Bone marrow megakaryocytes in patients treated with and without rhTPO at 3, 6, and 9 months (all P < 0.05).
Mentions: In patients treated with rhTPO, megakaryocyte counts (according to bone marrow biopsies of 1 cm × 1 cm) were 9 (n = 32, range 0–35) at 3 months, 13 (n = 31, range 0–41) at 6 months, and 32 (n = 29, range 0–79) at 9 months. The number of megakaryocytes in patients without rhTPO treatment was 3 (n = 37, range 0–5), 5 (n = 34, range 0–19), and 9 (n = 32, range 0–42) at 3, 6, and 9 months, respectively. In our study, there was a significant increase of megakaryocytes in patients treated with rhTPO at 3, 6, and 9 months (P = 0.025, P = 0.021, and P = 0.011, resp.) (Table 3, Figure 1).

Bottom Line: Hematologic response, bone marrow megakaryocyte recovery, and time to transfusion independence were compared.Subjects receiving rhTPO presented an elevated number of megakaryocytes at 3, 6, and 9 months when compared with those without treatment (P = 0.025, P = 0.021, and P = 0.011, resp.).Overall survival rate presented no differences between the two groups. rhTPO could improve hematologic response and promote bone marrow recovery in SAA patients receiving IST.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, General Hospital, Tianjin Medical University, Tianjin 300052, China.

ABSTRACT

Objective: To assess the effectiveness of recombinant human thrombopoietin (rhTPO) in severe aplastic anemia (SAA) patients receiving immunosuppressive therapy (IST).

Methods: Eighty-eight SAA patients receiving IST from January 2007 to December 2012 were included in this retrospective analysis. Of these, 40 subjects received rhTPO treatment (15000 U, subcutaneously, three times a week). rhTPO treatment was discontinued when the platelet count returned to normal range. Hematologic response, bone marrow megakaryocyte recovery, and time to transfusion independence were compared.

Results: Hematologic response was achieved in 42.5%, 62.5%, and 67.5% of patients receiving rhTPO and 22.9%, 41.6%, and 47.9% of patients not receiving rhTPO at 3, 6, and 9 months after treatment, respectively (P = 0.0665, P = 0.0579, and P = 0.0847, resp.). Subjects receiving rhTPO presented an elevated number of megakaryocytes at 3, 6, and 9 months when compared with those without treatment (P = 0.025, P = 0.021, and P = 0.011, resp.). The time to platelet and red blood cell transfusion independence was shorter in patients who received rhTPO than in those without rhTPO treatment. Overall survival rate presented no differences between the two groups.

Conclusion: rhTPO could improve hematologic response and promote bone marrow recovery in SAA patients receiving IST.

Show MeSH
Related in: MedlinePlus